Loading stock data…
IMNM
$23.04-0.08 (-0.35%)
Market OpenUpdated 12:05 PM EDT
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunome, Inc. in the Healthcare sector is trading at $23.04. The stock is currently 17% below its 52-week high of $27.65, remaining 29.3% above its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why IMNM maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$23.04
Potential Upside
5%
Whystock Fair Value$24.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Mean target$35.54+54.2%
Range$30.00 – $40.00
Fundamentals
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset compris...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.65B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.14
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.83%
Volume
Today's trading volume
113,083
Recent News
Techne (TECH) Misses Q3 Earnings and Revenue Estimates
Techne (TECH) delivered earnings and revenue surprises of -2.75% and -2.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Tops Q1 Earnings Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +15.55% and -0.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -12.39% and -82.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing
Immunome (IMNM) is back in focus after announcing that Phase 3 data for its desmoid tumor drug candidate, varegacestat, will be featured in an oral session at the 2026 ASCO Annual Meeting. The company also plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second quarter of 2026, a step that moves this program closer to a potential commercial decision point. See our latest analysis for Immunome. The latest ASCO and FDA milestones come after a mixed trading...
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
This biotech innovator in antibody therapeutics reported a notable insider sale amid a year of dramatic share price gains.